LeMaitre Vascular (NASDAQ:LMAT) Director Sells $560,388.40 in Stock

Posted by Brian Himes on May 11th, 2026

LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) Director Bridget Ross sold 5,044 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the transaction, the director owned 3,942 shares in the company, valued at $437,956.20. The trade was a 56.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT traded down $6.30 during midday trading on Monday, reaching $101.64. The stock had a trading volume of 410,363 shares, compared to its average volume of 209,885. LeMaitre Vascular, Inc. has a 1-year low of $78.35 and a 1-year high of $118.01. The firm’s fifty day simple moving average is $110.00 and its 200-day simple moving average is $94.48. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. The stock has a market capitalization of $2.32 billion, a P/E ratio of 37.51, a PEG ratio of 3.00 and a beta of 0.60.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. During the same period last year, the business posted $0.48 EPS. LeMaitre Vascular’s revenue was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post 3 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Thursday, May 21st will be paid a $0.25 dividend. The ex-dividend date is Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 36.90%.

Analysts Set New Price Targets

A number of research firms recently issued reports on LMAT. Barrington Research raised their target price on shares of LeMaitre Vascular from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Citizens Jmp raised their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Wells Fargo & Company raised their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $112.60.

Read Our Latest Research Report on LeMaitre Vascular

Institutional Trading of LeMaitre Vascular

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Catalyst Capital Advisors LLC acquired a new stake in LeMaitre Vascular in the 1st quarter worth $32,000. Bessemer Group Inc. grew its position in LeMaitre Vascular by 292.3% in the 1st quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier’s stock worth $18,759,000 after purchasing an additional 128,033 shares during the last quarter. Illumine Investment Management LLC grew its position in LeMaitre Vascular by 3.8% in the 1st quarter. Illumine Investment Management LLC now owns 14,874 shares of the medical instruments supplier’s stock worth $1,624,000 after purchasing an additional 538 shares during the last quarter. Principal Financial Group Inc. grew its position in LeMaitre Vascular by 4.3% in the 1st quarter. Principal Financial Group Inc. now owns 117,840 shares of the medical instruments supplier’s stock worth $12,865,000 after purchasing an additional 4,874 shares during the last quarter. Finally, Hardy Reed LLC acquired a new stake in LeMaitre Vascular in the 1st quarter worth $254,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

(Get Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.